title: Severity of hematuria effects resolution in patients treated with hyperbaric oxygen therapy for radiation-induced hematuria.
abstract: BACKGROUND
  We investigated the differences between prostate cancer patients with radiation-induced hematuria treated with hyperbaric oxygen (HBO) therapy that did or did not have a resolution of hematuria.
  
  
  METHODS
  We performed a retrospective review of prostate cancer patients with radiation-induced hematuria who underwent HBO from April 2000 to March 2010. We performed an analysis of demographic data and severity of hematuria in those who had resolution of or persistent hematuria. Additionally, prostate-specific antigen (PSA) data were also obtained during the study period.
  
  
  RESULTS
  Overall, 11/22 men had resolution of hematuria after HBO therapy with a median follow-up of 2.2 (0.35-13.6) years. The Radiation Therapy Oncology Group (RTOG) grade of hematuria is predictive of final hematuria outcome (resolution vs. persistent) after HBO (p = 0.026). No significant PSA changes were noted before and after HBO therapy.
  
  
  CONCLUSIONS
  The RTOG hematuria grade is associated with the resolution of hematuria after HBO therapy for radiation-induced hematuria in men treated for prostate cancer. This information may be helpful during shared medical decision-making regarding utility of HBO therapy in the context of severity of hematuria.
authors.affiliation: Departments of Urology and Medicine, University of California - Irvine, Orange, Calif., USA.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Liss
authors.forename: Kathryn
authors.initials: K
authors.lastname: Osann
authors.forename: Jane
authors.initials: J
authors.lastname: Cho
authors.forename: Walter C
authors.initials: WC
authors.lastname: Chua
authors.forename: Atreya
authors.initials: A
authors.lastname: Dash
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003556:Cystitis / Q000209:etiology / Q000628:therapy; D003657:Decision Making; D006417:Hematuria / Q000097:blood / Q000209:etiology* / Q000628:therapy*; D006801:Humans; D006931:Hyperbaric Oxygenation / Q000379:methods*; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000150:complications / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000628:therapy; D011878:Radiotherapy / Q000009:adverse effects; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D017430:Prostate-Specific Antigen
references.citation: J Urol. 1991 Sep;146(3):798-802
references.pmid: 1908530
references.citation: Gynecol Oncol. 1994 Nov;55(2):206-10
references.pmid: 7959285
references.citation: World J Surg. 2006 Dec;30(12):2112-31
references.pmid: 17102915
references.citation: Int J Radiat Oncol Biol Phys. 1991 Sep;21(4):935-9
references.pmid: 1917622
references.citation: J Urol. 1992 Mar;147(3 Pt 2):926-8
references.pmid: 1538499
references.citation: Undersea Hyperb Med. 1994 Dec;21(4):467-75
references.pmid: 8000286
references.citation: J Urol. 2003 Jun;169(6):2200-2
references.pmid: 12771749
references.citation: Urol Int. 2010;84(4):467-70
references.pmid: 20224264
references.citation: J Hematol Oncol. 2010 Aug 02;3:26
references.pmid: 20678204
references.citation: Lancet. 1995 Sep 23;346(8978):803-5
references.pmid: 7674746
references.citation: In Vitro Cell Dev Biol Anim. 1999 Feb;35(2):98-101
references.pmid: 10475264
references.citation: Eur Urol. 2001 Aug;40(2):111-23
references.pmid: 11528186
references.citation: J Urol. 1999 Feb;161(2):435-7
references.pmid: 9915420
references.citation: Radiother Oncol. 2007 Aug;84(2):197-215
references.pmid: 17532494
references.citation: Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74
references.pmid: 16798415
references.citation: Zhonghua Nan Ke Xue. 2009 Aug;15(8):713-6
references.pmid: 19852272
references.citation: Arch Esp Urol. 2011 Nov;64(9):869-74
references.pmid: 22155874
references.citation: J Urol. 1993 Aug;150(2 Pt 1):332-4
references.pmid: 8326555
references.citation: BJU Int. 2004 Dec;94(9):1275-8
references.pmid: 15610104